Consensus Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
9.91 USD +3.34% Intraday chart for Arcutis Biotherapeutics, Inc. -8.24% +206.81%

Evolution of the average Target Price on Arcutis Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

8cd07.RA9jitZkYvD2SXM3H8WoR9JzPaCKPX7LFtKGjYDFQlw.Pj8BxYA0BpSfIh11b6jRF7scBeLEUTX8cobq4rm9Ejoudw_puggThaAiKg~edcaa1eb4aaa702cd8ef39c3897e875b
Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating MT
Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating MT
Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating MT
Mizuho Upgrades Arcutis Biotherapeutics to Buy From Neutral, Raises Price Target to $8 From $4 MT
Exchange-Traded Funds Mixed; US Equities Rise Pre-Bell Monday as Investors Hope for Federal Reserve Rate Cuts Soon MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight Rating MT
JonesTrading Downgrades Arcutis Biotherapeutics to Hold From Buy MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $8 From $22, Maintains Buy Rating MT
Mizuho Downgrades Arcutis Biotherapeutics to Neutral From Buy MT
Goldman Sachs Downgrades Arcutis Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $32 MT
Truist Securities Lowers Price Target on Arcutis Biotherapeutics to $40 From $45, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $33 From $44, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $45 From $47, Maintains Overweight Rating MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $57 From $61, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $47 From $50, Keeps Overweight Rating MT
Truist Securities Lowers Arcutis Biotherapeutics' Price Target to $45 From $50, Maintains Buy Rating MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $24 From $46, Maintains Buy Rating MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $50 From $51, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $51 From $49, Maintains Overweight Rating MT
Morgan Stanley Adjusts Arcutis Biotherapeutics' Price Target to $49 from $46, Maintains Overweight Rating MT
Morgan Stanley Lifts Price Target on Arcutis Biotherapeutics to $46 From $45, Reiterates Overweight Rating MT
JonesTrading Assumes Arcutis Biotherapeutics at Buy with $54 Price Target MT
Needham Starts Arcutis Biotherapeutics at Buy With $46 Price Target MT
Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $50 From $45, Reiterates Buy Rating MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $45 From $39, Reiterates Overweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.91 USD
Average target price
18 USD
Spread / Average Target
+81.63%
High Price Target
26 USD
Spread / Highest target
+162.36%
Low Price Target
11 USD
Spread / Lowest Target
+11.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arcutis Biotherapeutics, Inc.

Mizuho Securities
Needham & Co.
Morgan Stanley
JonesTrading Institutional Services
Goldman Sachs
Truist Securities
Guggenheim
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings